Australia Stock Exchange release from CHIMERIC THERAPE : Final Results in Phase 1 Trial of CORE NK Platform
06/03/2022 23:17
Australia Stock Exchange release from CHIMERIC THERAPE CHM.AX : Final Results in Phase 1 Trial of CORE NK Platform
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial